K. Zejnullahu

发表

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

P. Jänne, Bruce E. Johnson, J. Engelman, 2006, The Journal of clinical investigation.

The Increasing Dominance of Teams in Production of Knowledge

Joon-Oh Park, F. Cappuzzo, L. Cantley, 2011 .

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Joon-Oh Park, P. Jänne, Bruce E. Johnson, 2007, Science.

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

P. Jänne, F. Cappuzzo, K. Okuno, 2011, Science Translational Medicine.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Luca Toschi, A. Iafrate, P. Jänne, 2010, Cancer cell.

Approaches to minimize castration in the treatment of advanced prostate cancer.

K. Zejnullahu, C. Ryan, R. Aggarwal, 2016, Urologic oncology.

OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

P. Jänne, J. Engelman, K. Zejnullahu, 2011 .

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

H. Varmus, J. Bradner, K. Zejnullahu, 2012, Proceedings of the National Academy of Sciences.

Diffuse Alveolar Hemorrhage: Blood, Sweat and Tears

K. Zejnullahu, R. Manesh, S. Khatami, 2016, Journal of General Internal Medicine.

Mycoplasma pneumoniae-Induced Rash and Mucositis in a Previously Healthy Man: A Case Report and Brief Review of the Literature

K. Zejnullahu, R. Edson, Elizabeth Y. Kim, 2020, Open forum infectious diseases.

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

P. Jänne, K. Zejnullahu, N. Lindeman, 2008, Clinical Cancer Research.

High‐Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer

K. Zejnullahu, E. Small, L. Fong, 2017, Clinical genitourinary cancer.

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Derek Y. Chiang, Matthew Meyerson, William G. Richards, 2008, Clinical Cancer Research.

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

Harold Varmus, H. Varmus, K. Zejnullahu, 2015, eLife.

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

M. Meyerson, P. Jänne, Kwok-Kin Wong, 2007, Cancer research.

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

P. Jänne, J. Engelman, J. Christensen, 2010, Oncogene.

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.

P. Jänne, Kwok-Kin Wong, N. Gray, 2013, Cancer research.

Therapeutics , Targets , and Chemical Biology Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF 1 R Pathway

Kwok-Kin Wong, N. Gray, J. Christensen, 2013 .

Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF 1 R Pathway

P. Jänne, N. Gray, J. Christensen, 2012 .

Stefan Wuchty , of Knowledge The Increasing Dominance of Teams in Production

Joon-Oh Park, F. Cappuzzo, L. Cantley, 2009 .

Author response: Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

H. Varmus, K. Zejnullahu, S. Lee-Lin, 2015 .

The Increasing Dominance of Teams in Production of Knowledge

Joon-Oh Park, F. Cappuzzo, L. Cantley, 2014 .

Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab

P. Jänne, K. Zejnullahu, M. Fukuoka, 2012 .